My life as a lab rat

I'm on the cutting edge of a promising new cancer treatment – if it doesn't kill me first

Topics: Cancer, Life stories,

My life as a lab rat (Credit: iStockphoto/lculig)

The news couldn’t have been much worse. The timing couldn’t have been much better.

In August, one relatively healthy year after losing five centimeters of my scalp to malignant melanoma, my doctor told me there were some “troubling” new spots on my lungs – and that they were growing. A few weeks later, I awoke from the surgical biopsy, doped up and under an oxygen mask, and had my worst fears confirmed – the spots were malignant. Two weeks later, after I pointed out a peculiar bruise on my back during a routine follow-up, the diagnosis got even worse – that bruise was another malignant tumor.

In the space of days, I’d gone from someone whose friends had hastily branded a “survivor” to a woman with metastatic, Stage 4 cancer. But just as I was  blubbering through the news, my oncologist offered a life raft in a sea of panic. She explained that my immunologist, who’d recently led the clinical trials for Ipilimumab, the first new melanoma drug approved by the FDA in 30 years, was doing a new, Phase 1 clinical trial. It would combine Ipilimumab with another promising experimental drug, MDX-1106, and for a longer course of treatment. As an otherwise young, healthy person, I was a suitable candidate for the sole upcoming spot in the trial.

When Ipilimumab was approved last spring, doctors crowed of its success in extending lives by entire months, and its 30 percent success rate. “In cancer,” my oncologist had said, “that’s a home run.” Those odds feel considerably less bright when you’re the one with cancer, but the treatment nonetheless offered hope. And with that, I became one of the fewer than two dozen people with advanced melanoma in America right now lucky enough to be Bristol-Myers Squibb’s little lab rodent.

But first, before beginning the trial, I had to submit to a battery of grueling tests and interviews, both to “establish a baseline” and to assure that I qualified as a subject. It was kind of like going for a high-level job, except that I wasn’t sure how to ace an MRI and CT scan. For weeks, I dragged my freaked-out ass back and forth to Sloan-Kettering, meekly answering questions and suppressing fits of giggles every time someone tried to check the lymph nodes under my arms.

Though the field is still relatively new, immunotherapy has the potential to be one of the first true game-changers in cancer treatment to come along in ages. Unlike chemotherapy, it works with the body’s own defenses to fight off cancer. And unlike chemo, the side effects tend to be more tolerable – and less intimidating to patients. As one of my nurses recently explained, “There are people who avoid treatment because they’re afraid of chemo. They see people who’ve lost their hair and lost weight, people who are throwing up. They don’t want to look sick.” Aside from its potential effectiveness, immunotherapy is quite literally an opportunity to put a new face on the public perception of treatment — one that doesn’t say to colleagues and strangers on the street,  “As you can see from my bald, fragile countenance, I have some messed up cancer here.”

Yet there are risks with every drug — as you’ve probably ascertained from those horrifying ads for Abilify. And if you ever really want to feel like you’re chemically tempting the fates, I recommend a Phase 1 clinical trial. On the list of subjects on whom my drug combination has been tried, I think I’m right behind that monkey from “28 Days Later.”

I realized my life was about to get intense when I was handed a 27-page informed consent form alerting me of my “responsibilities.” I was not to get a flu shot. I “must not” get pregnant. As a mother in her mid-40s, that one wasn’t a hard sell, but I wondered how that imperative is going over for my fellow subjects. I had to agree that I understand I would run the risk of a battery of side effects from fever, rash and fatigue to “rare but serious” conditions ranging from heart attacks to meningitis.

At one early meeting, a doctor on the study had me sit on the exam table, surrounded by young residents and fellows. He prodded the tumor on my back, pointing out its size and coloration, marveling at its dimensions, seemingly unaware that there was breathing human attached to it.

“My oncologist says she can remove it,” I piped up. Unlike the cancer in my lung, the tumor was at least easy to access. He looked momentarily stunned, as if he hadn’t expected his research animal to pipe up with an opinion.

“No,” he replied firmly. “If you remove the tumor, you can’t be in the study. We need it.”

I never saw that doctor again, which is fortunate because I told the rest of the team that I never wanted that man to touch me, ever. My immunologist, meanwhile, cleared me to have the back tumor removed if I still wanted. But by then, I’d begun the treatment, and amazing things had already started happening.

“It’s smaller,” the immunologist said a week after my first infusion. “Look how flat that is. Is this tender to the touch?” he asked. It wasn’t. Two weeks after the first treatment, the doctor was already enthusing to his colleagues at a medical gathering in Washington, D.C., about the patient who’d visibly improved after just one treatment. We’ll see what’s brewing in my lung when I go for my next CT scan in December, but so far, I am considered quite the achiever around the fourth floor. My doctor beams at me like I’m Christmas morning.

Yet it isn’t all a happy cakewalk through cancer yet. Though I’m faring well by most standards, the side effects have kicked in – and, I know, may well escalate as I continue treatment. The morning run I used to fly through can now make me cry with exhaustion. Last week, a dash up the stairs of my child’s school rendered me so out of breath I couldn’t speak. The diarrhea hasn’t been too bad, though my doctors could ask me about it all day long. I am beginning to think they suspect the Da Vinci Code is hidden somewhere in my defecatory habits.

And then there is the ongoing fear that the treatment will stop working — or perhaps more agonizingly — keep working but become too dangerous to continue. Last summer, a dear friend was thriving on Avastin, until a sudden, harrowing reaction landed her in the hospital. She was pulled off treatment, and just last week the FDA withdrew approval for its use for breast cancer. The scary truth is that many of us in the cancer world — both doctors and patients — are winging it here, just hoping that the cure doesn’t kill us along the way.

I also still can’t get my head around the stunning amount of money this thing is costing. A regular course of four Ipilimumab treatments runs a whopping $120,000. I am getting double that, not including the maintenance phase treatment, in combination with the MDX-1106. Because I’m in a trial, Bristol-Myers Squibb, not my insurer, is paying for the drugs. Yet I couldn’t help cringing recently when I couldn’t do a treatment because my temperature suddenly spiked. As he readied me to go home, one of my doctors pointed to the fat bags of now useless drugs at my side and the two Tylenol in my hand and joked, “I’d say this was a $25,000 day.”

But aside from the free lunch I get every time I go for treatment, there is no free lunch. Whether I have a treatment or not, I am expected to go to Sloan-Kettering every week for monitoring and blood work. They usually take a dozen vials, sometimes squeezing my arms to coax the fluid out of my reluctant veins. I have a six-month initial course of treatment, followed by a nearly two-year, eased-up “maintenance” course, followed by a long-term relationship of follow-up study. Assuming I don’t die, I will be, as a nurse told me early on, “working with us for, I guess, forever.”

It is costing a lot to keep me alive these days. But I hope I’m contributing something too. I’ve signed off on giving my blood and tissue and whatever the hell else anybody wants to have for genetic studies, for research into other forms of cancer, for the treatment of other deadly diseases. On my better days, I feel connected to something very big. I feel like my diseased body has a purpose. And then sometimes I feel like a combination of Henrietta Lacks, those kids from “Never Let Me Go” and Michael Palin’s doomed brood in “Monty Python’s the Meaning of Life.”

I am an experiment. And as the experiment continues, I intend to keep sharing it with you, giving you my take on what it’s like to both grapple with a potentially fatal illness, and to stand on the front lines of a treatment that just might revolutionize cancer care. Right now, I have a light, speckled rash all over my body, a condition I hope a new steroid cream will correct. My gums sometimes bleed. I have a slick, oily taste in my mouth, one that rendered the birthday cake my family made for me recently all but inedible. Yet when my daughters grandly marched it out from the kitchen, I smiled gamely and posed for pictures. Then I made a wish. Not just for me, but for all of us living here in Stage 4, and for all those yet to someday get that devastating, life-changing phone call. Let all this be worth it, I thought. Let it work. And I blew out the candles.

Mary Elizabeth Williams

Mary Elizabeth Williams is a staff writer for Salon and the author of "Gimme Shelter: My Three Years Searching for the American Dream." Follow her on Twitter: @embeedub.

More Related Stories

Featured Slide Shows

  • Share on Twitter
  • Share on Facebook
  • 1 of 11
  • Close
  • Fullscreen
  • Thumbnails

    Ten spectacular graphic novels from 2014

    Beautiful Darkness by Fabien Vehlmann & Kerascoët
    Kerascoët's lovely, delicate pen-and-watercolor art -- all intricate botanicals, big eyes and flowing hair -- gives this fairy story a deceptively pretty finish. You find out quickly, however, that these are the heartless and heedless fairies of folk legend, not the sentimental sprites beloved by the Victorians and Disney fans. A host of tiny hominid creatures must learn to survive in the forest after fleeing their former home -- a little girl who lies dead in the woods. The main character, Aurora, tries to organize the group into a community, but most of her cohort is too capricious, lazy and selfish to participate for long. There's no real moral to this story, which is refreshing in itself, beyond the perpetual lessons that life is hard and you have to be careful whom you trust. Never has ugly truth been given a prettier face.

    Ten spectacular graphic novels from 2014

    Climate Changed: A Personal Journey Through the Science by Philippe Squarzoni
    Squarzoni is a French cartoonist who makes nonfiction graphic novels about contemporary issues and politics. While finishing up a book about France under Jacques Chirac, he realized that when it came to environmental policy, he didn't know what he was talking about. "Climate Changed" is the result of his efforts to understand what has been happening to the planet, a striking combination of memoir and data that ruminates on a notoriously elusive, difficult and even imponderable subject. Panels of talking heads dispensing information (or Squarzoni discussing the issues with his partner) are juxtaposed with detailed and meticulous yet lyrical scenes from the author's childhood, the countryside where he takes a holiday and a visit to New York. He uses his own unreachable past as a way to grasp the imminent transformation of the Earth. The result is both enlightening and unexpectedly moving.

    Ten spectacular graphic novels from 2014

    Here by Richard McGuire
    A six-page version of this innovative work by a regular contributor to the New Yorker first appeared in RAW magazine 25 years ago. Each two-page spread depicts a single place, sometimes occupied by a corner of a room, over the course of 4 billion years. The oldest image is a blur of pink and purple gases; others depict hazmat-suited explorers from 300 years in the future. Inset images show the changing decor and inhabitants of the house throughout its existence: family photos, quarrels, kids in Halloween costumes, a woman reading a book, a cat walking across the floor. The cumulative effect is serene and ravishing, an intimation of the immensity of time and the wonder embodied in the humblest things.

    Ten spectacular graphic novels from 2014

    Kill My Mother by Jules Feiffer
    The legendary Pulitzer Prize-winning cartoonist delivers his debut graphic novel at 85, a deliriously over-the-top blend of classic movie noir and melodrama that roams from chiaroscuro Bay City to Hollywood to a USO gig in the Pacific theater of World War II. There's a burnt-out drunk of a private eye, but the story is soon commandeered by a multigenerational collection of ferocious women, including a mysterious chanteuse who never speaks, a radio comedy writer who makes a childhood friend the butt of a hit series and a ruthless dame intent on making her whiny coward of a husband into a star. There are disguises, musical numbers and plenty of gunfights, but the drawing is the main attraction. Nobody convey's bodies in motion more thrillingly than Feiffer, whether they're dancing, running or duking it out. The kid has promise.

    Ten spectacular graphic novels from 2014

    The Motherless Oven by Rob Davis
    This is a weird one, but in the nervy surreal way that word-playful novels like "A Clockwork Orange" or "Ulysses" are weird. The main character, a teenage schoolboy named Scarper Lee, lives in a world where it rains knives and people make their own parents, contraptions that can be anything from a tiny figurine stashable in a pocket to biomorphic boiler-like entities that seem to have escaped from Dr. Seuss' nightmares. Their homes are crammed with gadgets they call gods and instead of TV they watch a hulu-hoop-size wheel of repeating images that changes with the day of the week. They also know their own "death day," and Scarper's is coming up fast. Maybe that's why he runs off with the new girl at school, a real troublemaker, and the obscurely dysfunctional Castro, whose mother is a cageful of talking parakeets. A solid towline of teenage angst holds this manically inventive vision together, and proves that some graphic novels can rival the text-only kind at their own game.

    Ten spectacular graphic novels from 2014

    NOBROW 9: It's Oh So Quiet
    For each issue, the anthology magazine put out by this adventurous U.K.-based publisher of independent graphic design, illustration and comics gives 45 artists a four-color palette and a theme. In the ninth issue, the theme is silence, and the results are magnificent and full of surprises. The comics, each told in images only, range from atmospheric to trippy to jokey to melancholy to epic to creepy. But the two-page illustrations are even more powerful, even if it's not always easy to see how they pertain to the overall concept of silence. Well, except perhaps for the fact that so many of them left me utterly dumbstruck with visual delight.

    Ten spectacular graphic novels from 2014

    Over Easy by Mimi Pond
    When Pond was a broke art student in the 1970s, she took a job at a neighborhood breakfast spot in Oakland, a place with good food, splendid coffee and an endlessly entertaining crew of short-order cooks, waitresses, dishwashers and regular customers. This graphic memoir, influenced by the work of Pond's friend, Alison Bechdel, captures the funky ethos of the time, when hippies, punks and disco aficionados mingled in a Bay Area at the height of its eccentricity. The staff of the Imperial Cafe were forever swapping wisecracks and hopping in and out of each other's beds, which makes them more or less like every restaurant team in history. There's an intoxicating esprit de corps to a well-run everyday joint like the Imperial Cafe, and never has the delight in being part of it been more winningly portrayed.

    Ten spectacular graphic novels from 2014

    The Shadow Hero by Gene Luen Yang and Sonny Liew
    You don't have to be a superhero fan to be utterly charmed by Yang and Liew's revival of a little-known character created in the 1940s by the cartoonist Chu Hing. This version of the Green Turtle, however, is rich in characterization, comedy and luscious period detail from the Chinatown of "San Incendio" (a ringer for San Francisco). Hank, son of a mild-mannered grocer, would like to follow in his father's footsteps, but his restless mother (the book's best character and drawn with masterful nuance by Liew) has other ideas after her thrilling encounter with a superhero. Yang's story effortlessly folds pathos into humor without stooping to either slapstick or cheap "darkness." This is that rare tribute that far surpasses the thing it celebrates.

    Ten spectacular graphic novels from 2014

    Shoplifter by Michael Cho
    Corinna Park, former English major, works, unhappily, in a Toronto advertising agency. When the dissatisfaction of the past five years begins to oppress her, she lets off steam by pilfering magazines from a local convenience store. Cho's moody character study is as much about city life as it is about Corinna. He depicts her falling asleep in front of the TV in her condo, brooding on the subway, roaming the crowded streets after a budding romance goes awry. Like a great short story, this is a simple tale of a young woman figuring out how to get her life back, but if feels as if it contains so much of contemporary existence -- its comforts, its loneliness, its self-deceptions -- suspended in wintery amber.

    Ten spectacular graphic novels from 2014

    Through the Woods by Emily Carroll
    This collection of archetypal horror, fairy and ghost stories, all about young girls, comes lushly decked in Carroll's inky black, snowy white and blood-scarlet art. A young bride hears her predecessor's bones singing from under the floorboards, two friends make the mistake of pretending to summon the spirits of the dead, a family of orphaned siblings disappears one by one into the winter nights. Carroll's color-saturated images can be jagged, ornate and gruesome, but she also knows how to chill with absence, shadows and a single staring eye. Literary readers who cherish the work of Kelly Link or the late Angela Carter's collection, "The Bloody Chamber," will adore the violent beauty on these pages.

  • Recent Slide Shows



Comment Preview

Your name will appear as username ( settings | log out )

You may use these HTML tags and attributes: <a href=""> <b> <em> <strong> <i> <blockquote>